Lipocine Seeks Brilzio Partner, Eyes Phase 2 Filings for CNS Pipeline
LPCN sits 18% above its 52-week low of $1.81.
Summary
Lipocine is actively seeking partners for Brilzio, its postpartum depression candidate, while evaluating LPCN-2201 (MDD) and LPCN-2203 (essential tremor) for potential Phase 2 filings. This follows the Q2 report on August 4 showing a $2.6M loss and $23.3M cash, with revenue down 69.5%. The partner search signals a strategic shift to share development costs and risk after the failed Phase 3 for LPCN 1154. An FDA meeting in Q3 will determine the regulatory path for the lead PPD drug, making the next few months critical for the pipeline's direction.
At the time of this announcement, LPCN was trading at $2.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.6M. The 52-week trading range was $1.81 to $12.37. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.